cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Triple-negative breast cancer (TNBC) frequently exhibits epidermal growth factor receptor (EGFR) expression and pathway activation.
• Current anti-EGFR therapies have shown limited efficacy in TNBC patients, suggesting resistance mechanisms.
• The role of MET receptor tyrosine kinase in overcoming EGFR therapy resistance in TNBC warrants investigation.

Purpose of the Study:

• To investigate the efficacy of targeting MET in overcoming resistance to EGFR therapy in TNBC cell lines.
• To evaluate the synergistic effects of combined EGFR and MET inhibition in TNBC models.

Main Methods:

• Utilized TNBC cell lines (MDA-MB-468, HCC-1395, MDA-MB-231) and a hormone receptor-positive line (T47D).
• Stimulated cells with epidermal growth factor (EGF) and hepatocyte growth factor (HGF).
• Treated cells with EGFR inhibitors (gefitinib, cetuximab) alone or in combination with a MET inhibitor (EMD 1214063), assessing proliferation via MTS, soft agar, and matrigel assays. Synergy was quantified using Calcusyn, and protein signaling was analyzed by immunoblotting.

Main Results:

• Observed activation of ligand-receptor-downstream signaling pathways in response to EGF and HGF in MDA-MB-468 and HCC-1395 cells.
• Demonstrated synergistic effects when combining EGFR and MET inhibitors across multiple assays in these TNBC lines.
• Combination therapy led to the abrogation of pAKT and pMAPK signaling, unlike monotherapy.

Conclusions:

• Dual inhibition of EGFR and MET demonstrates synergistic activity in triple-negative breast cancer.
• Targeting both EGFR and MET receptors concurrently presents a potentially effective therapeutic strategy for TNBC.